Superdrol (Methasterone) — Dosing, Cycles, Half-Life & Side Effects

Superdrol (Methasterone) is an oral anabolic-androgenic steroid with a half-life of 8-12 hours. Potent designer steroid for rapid mass and strength gains, highly hepatotoxic. Primary risks include significant hepatotoxicity, strong HPTA suppression, liver stress typical of 17α-alkylated orals. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.

Quick Facts

ClassOrals
Half-life8-12 hours
Detection window90 days
AromatizationNo
HepatotoxicityVery High
Suppression9/10
17α-alkylatedYes
Administrationoral

Typical Dosing Ranges

Common dose range: 10-30mg/day

Cycle length: 3-4 weeks

Time to steady state: ~2 days

Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.

Stacking Considerations

PCT Requirements

  • This compound causes clinically meaningful HPTA suppression. Post-cycle therapy is recommended.
  • Depot clearance estimate: ~2 days post-last-dose before SERM start (5 × apparent depot half-life of 8h).
  • Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
  • Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.

Side Effect Profile

  • Severe hepatotoxicity
  • Extreme suppression
  • Methylated compound
  • Harsh on lipids

Known Interactions

  • Superdrol is extremely hepatotoxic. Any combination increases risk.

    Recommendation: Superdrol should never be combined with other orals.

    Monitor: Full liver panel every 3 days

Monitoring (Bloodwork & Vitals)

  • Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
  • Lipid panel (total cholesterol, HDL, LDL, triglycerides)
  • CBC (hemoglobin, hematocrit — watch for erythrocytosis)
  • Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
  • Liver enzymes (ALT, AST, GGT) every 2–4 weeks on oral 17αα cycles
  • Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)

Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.

Frequently Asked Questions

What is the half-life of Superdrol (Methasterone)?

Superdrol (Methasterone) has a half-life of approximately 8-12 hours. Clearance estimate: 8h � 5 = 40h = 1.7 days. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.

What is the typical dose range for Superdrol (Methasterone)?

Commonly reported ranges for Superdrol (Methasterone): 10-30mg/day. Cycle length: 3-4 weeks. These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.

Does Superdrol (Methasterone) suppress natural testosterone?

Superdrol (Methasterone) causes severe suppression of the HPTA axis (score 9/10). Post-cycle therapy (PCT) is recommended after use.

Is Superdrol (Methasterone) liver toxic?

Hepatotoxicity rating: Very High. Superdrol (Methasterone) is 17α-alkylated, which bypasses first-pass liver metabolism and increases hepatic stress. Oral 17αα cycles should be capped at 6 weeks and paired with liver monitoring (ALT/AST every 2–4 weeks).

Does Superdrol (Methasterone) aromatize to estrogen?

Aromatization profile: No. Minimal to no aromatization expected, so aromatase inhibitors are not typically indicated for this compound alone.

What is Superdrol (Methasterone) typically used for?

Superdrol (Methasterone) is commonly used for: Bulking, Strength cycles, Advanced users only. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.

Citations

  1. DILI case series. 2020. Clinical case reports (multiple) — Half-life 8-9 hours for methyldrostanolone; among the most hepatotoxic oral AAS documented
  2. DILI case series. 2020. Clinical case reports — Cholestatic jaundice with bilirubin up to 50 mg/dL; 43% of cases showing kidney injury; peliosis hepatis reported
  3. Liu et al.. 2025. Substance Use & Misuse — AAS meta-analysis: SBP +12.43 mmHg (95% CI: 9.59-15.26), LDL-C +9.12 mg/dL (95% CI: 6.75-11.49)
  4. Abeles RD, Foxton M, Khan S et al.. 2020. BMJ Open Gastroenterol — RUCAM-causality systematic review of 52 AAS-DILI cases: methyldrostanolone (Superdrol) was the MOST COMMON offending agent. Peak bilirubin 705 μmol/L, 43% developed concurrent kidney injury, bland canalicular cholestasis on biopsy, bilirubin peaks ~28d after cessation
  5. Niedfeldt MW. 2018. Curr Sports Med Rep — 17α-alkylation slows hepatic clearance, causing elevated transaminases, acute cholestatic syndrome, peliosis hepatis, and hepatic tumors; methasterone among most hepatotoxic
  6. Kicman AT. 2008. Br J Pharmacol — Designer steroid 17α-alkyl modifications confer oral activity at cost of severe hepatic toxicity; methasterone (2α,17α-dimethyl-DHT) was a prohormone-era designer compound banned by 2012 Designer Anabolic Steroid Control Act
  7. Hartgens F, Kuipers H. 2004. Sports Med — Potent oral non-aromatizing AAS produce profound and rapid HPTA suppression; supports suppressionScore 9/10
  8. Kędzierski J, Allard JA, Odermatt A, Smieško M. 2023. Toxicol Lett — In vitro mechanism: methasterone (among 14 AAS tested) inhibits AKR1D1 (5β-reductase) — explains bile acid synthesis disruption underlying AAS cholestasis; mechanistic biology for cholestatic syndrome documented clinically
  9. Narayanan R, Coss CC, et al. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol. 2008. PMID: 18801930

Disclaimer

StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use Superdrol (Methasterone). Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.

Skip to main content